Psychiatric Symptoms in Patients With Chronic Hepatitis C Receiving Interferon Alfa-2b Therapy
The DOI matches its Crossref record.
Abstract
BACKGROUND: Psychiatric side effects of interferon alfa are frequently observed in the therapy of patients with chronic hepatitis C infection. The goal of the present study was to assess prospectively the incidence, spectrum, and extent of psychiatric symptoms of patients receiving interferon alfa therapy as compared with an untreated reference group. METHOD: 104 patients with chronic hepatitis C were consecutively enrolled in a prospective longitudinal study. The treatment group (N = 84) received interferon alfa-2b for up to 12 months, and the reference group (N = 20) received no treatment. Patients who began treatment between November 1996 and August 1998 (N = 44) received interferon alfa-2b, 5 million units 3 times per week. Patients who began treatment in September 1998 or later (N = 40) received a combination of interferon alfa-2b, 3 to 5 million units 3 times per week, and ribavirin, 1000-1200 mg/day. Diagnostic scores for depression and anxiety were obtained by means of the psychometric instrument Hospital Anxiety and Depression Scale, and scores for anger/hostility were obtained with the Symptom Checklist-90 Revised. RESULTS: In contrast to the untreated reference group, we found significantly increased scores for depression (p <.001) and anger/hostility (p <.001) during interferon alfa therapy in the treatment group. Even before therapy, scores of those in the treatment group were above the respective cutoff values for clinically relevant symptoms of depression in 15.5% of the patients, anxiety in 13.1% of the patients, and anger/hostility in 11.3% of the patients. These proportions rose to 35.0% (depression), 25.6% (anxiety), and 24.5% (anger/hostility). The cumulative frequency of clinically relevant emotional distress (depression, anxiety, or anger/hostility) during interferon alfa therapy was 57.7%, as compared with 22.5% before therapy. However, interferon alfa therapy had to be stopped prematurely because of untreatable psychiatric symptoms in only 8.3% of patients. CONCLUSION: In view of the high frequency and extent of psychiatric symptoms with interferon alfa therapy, we recommend a close follow-up of patients receiving this therapy with respect to potential limiting mood changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment
Bisgaard, T. H., Allin, K. H., Keefer, L., Ananthakrishnan, A. N., & Jess, T. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00634-6 · Cited by 572
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Clinical consequences of cytochrome P450 2C9 polymorphisms
KIRCHHEINER, J., & BROCKMOLLER, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.009 · Cited by 474
Slavich, G. M., & Sacher, J. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05326-9 · Cited by 383
“Not all evidence consistently supports this finding and some research has found no sex differences in depressive symptoms following interferon-α treatment (Bonaccorso et al. 2002; Kraus et al. 2003; Miyaoka et al. 1999; see Raison et al. 2005).”
Capuron, L., Pagnoni, G., Drake, D. F., Woolwine, B. J., Spivey, J. R., Crowe, R. J., Votaw, J. R., Goodman, M. M., & Miller, A. H. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2094 · Cited by 382
Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy: Prevalence and Prediction
Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0106 · Cited by 299
Interferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07694 · Cited by 297
Academic Health Center Management of Chronic Diseases through Knowledge Networks: Project ECHO
Arora, S., Geppert, C. M. A., Kalishman, S., Dion, D., Pullara, F., Bjeletich, B., Simpson, G., Alverson, D. C., Moore, L. B., Kuhl, D., et al. (2007) · Academic Medicine · doi:10.1097/acm.0b013e31802d8f68 · Cited by 295
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.037 · Cited by 225
Felger, J. C., Alagbe, O., Hu, F., Mook, D., Freeman, A. A., Sanchez, M. M., Kalin, N. H., Ratti, E., Nemeroff, C. B., & Miller, A. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.026 · Cited by 214
Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors
Golden, J., O'Dwyer, A. M., & Conroy, R. M. (2005) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2005.06.006 · Cited by 211
Cazareth, J., Guyon, A., Heurteaux, C., Chabry, J., & Petit-Paitel, A. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-132 · Cited by 206
“Further evidence of the close link between inflammation and depression comes from clinical observations showing that patients receiving the pro-inflammatory cytokines IL-2 and interferon-α during cancer or hepatitis C treatments frequently develop major depression symptoms [17-19].”
BackgroundDepression and sterile inflammation: essential role of danger associated molecular patterns
Franklin, T. C., Xu, C., & Duman, R. S. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.10.025 · Cited by 204
Raison, C. L., Lowry, C. A., & Rook, G. A. W. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.161 · Cited by 169
“In support of the third prediction, that proinflammatory cytokine exposure should decrease tolerance of psychosocial adversity, interferon alfa treatment markedly increases irritability, which is at least as common as, and frequently more destructive to, interpersonal relationships than depression and fatigue.(218,219…”
Coccaro, E. F., Lee, R., & Coussons-Read, M. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3297 · Cited by 154
The role of inflammatory cytokines in suicidal behavior: A systematic review
Serafini, G., Pompili, M., Elena Seretti, M., Stefani, H., Palermo, M., Coryell, W., & Girardi, P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.06.002 · Cited by 151
Neuroinflammation in suicide: Toward a comprehensive model
Courtet, P., Giner, L., Seneque, M., Guillaume, S., Olie, E., & Ducasse, D. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1054879 · Cited by 146
“…studies suggesting that behavioural traits related to hostile, angry, and aggressive dispositions were associated with elevated infl ammatory markers, such as IL6 and CRP. Self-assessed anger and aggressive dispositions were greater in patients treated by cytokine immunotherapy (Kraus et al. 2003).”
BackgroundRAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03316.x · Cited by 142
Differences in cytokines between non-suicidal patients and suicidal patients in major depression
Kim, Y.-K., Lee, S.-W., Kim, S.-H., Shim, S.-H., Han, S.-W., Choi, S.-H., & Lee, B.-H. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.041 · Cited by 140
Raison, C. L., Rye, D. B., Woolwine, B. J., Vogt, G. J., Bautista, B. M., Spivey, J. R., & Miller, A. H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.019 · Cited by 116
Depression following pegylated interferon-alpha: Characteristics and vulnerability
Lotrich, F. E., Rabinovitz, M., Gironda, P., & Pollock, B. G. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.05.013 · Cited by 100
“Thirty-nine percent of euthymic subjects developed MDD, consistent with a growing literature [3,7,27-47], although this literature is complicated by retrospective, non-standardized diagnoses, and/or the present of active baseline mood disorder or antidepressants [23].”
ResultInflammation and lithium: clues to mechanisms contributing to suicide-linked traits
Beurel, E., & Jope, R. S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.129 · Cited by 92
Smith, A. K., Simon, J. S., Gustafson, E. L., Noviello, S., Cubells, J. F., Epstein, M. P., Devlin, D. J., Qiu, P., Albrecht, J. K., Brass, C. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.67 · Cited by 84
Jeon, S.-A., Lee, E., Hwang, I., Han, B., Park, S., Son, S., Yang, J., Hong, S., Kim, C. H., Son, J., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx065 · Cited by 62
“Additionally, patients undergoing type 1 interferon therapy showed a higher risk for psychiatric symptoms such as depression (Kraus et al., 2003), indicating that peripheral inflammation is frequently associated with depressive disorder.”
BackgroundFranzen, P. L., Buysse, D. J., Rabinovitz, M., Pollock, B. G., & Lotrich, F. E. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.02.011 · Cited by 62
Mood, cognition and EEG changes during interferon α (alpha-IFN) treatment for chronic hepatitis C
Amodio, P., De Toni, E. N., Cavalletto, L., Mapelli, D., Bernardinello, E., Del Piccolo, F., Bergamelli, C., Costanzo, R., Bergamaschi, F., Poma, S. Z., et al. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.09.004 · Cited by 61
Interferon therapy and its association with depressive disorders – A review
Lai, J. Y., Ho, J. X., Kow, A. S. F., Liang, G., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1048592 · Cited by 46
Emotions, immunity and sport: Winner and loser athlete’s profile of fighting sport
Pesce, M., Fratta, I. L., Ialenti, V., Patruno, A., Ferrone, A., Franceschelli, S., Rizzuto, A., Tatangelo, R., Campagna, G., Speranza, L., et al. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.02.013 · Cited by 44
Neri, S., Bertino, G., Petralia, A., Giancarlo, C., Rizzotto, A., Calvagno, G. S., Mauceri, B., Abate, G., Boemi, P., Di Pino, A., et al. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181d88af5 · Cited by 37
Feng, M., Crowley, N. A., Patel, A., Guo, Y., Bugni, S. E., & Luscher, B. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.003 · Cited by 20
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Kraus, M. R., Schafer, A., Faller, H., Csef, H., & Scheurlen, M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-06-15
- Volume
- 64
- Issue
- 6
- Pages
- 708-714
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2011809148
- Cited by
- 245
- References
- 0
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.